JGC
ABVX

J. Goldman & Co’s Abivax ABVX Stock Holding History

J. Goldman & Co’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,500
Closed -$4.11M – 645
2025
Q4 		$4.11M Buy
+30,500
New +$3.33M 0.11% 223

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

J. Goldman & Co's ABVX Position: Q1 2026 in Review

J. Goldman & Co increased its Abivax (ABVX) stake by 287% in Q1 2026, buying an estimated $1.12M and bringing the position to 12,749 shares worth $1.42M. The position accounts for 0.04% of the portfolio, ranked #375.

J. Goldman & Co first reported a position in ABVX in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.41M in Q3 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • J. Goldman & Co held 12,749 shares of Abivax worth $1.42M as of Q1 2026.
  • J. Goldman & Co bought 9,457 Abivax shares in Q1 2026, an estimated $1.12M.
  • Abivax made up 0.04% of J. Goldman & Co's portfolio in Q1 2026, its #375 holding.
  • J. Goldman & Co first reported a position in Abivax in Q2 2025 and has held it in 4 quarters since.
  • J. Goldman & Co's Abivax position peaked at $4.41M in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.